248 related articles for article (PubMed ID: 34090422)
1. Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making.
Kautz-Freimuth S; Redaèlli M; Rhiem K; Vodermaier A; Krassuski L; Nicolai K; Schnepper M; Kuboth V; Dick J; Vennedey V; Wiedemann R; Schmutzler R; Stock S
BMC Med Inform Decis Mak; 2021 Jun; 21(1):180. PubMed ID: 34090422
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial.
Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S
BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719
[TBL] [Abstract][Full Text] [Related]
5. Decision aids for female BRCA mutation carriers: a scoping review.
McGarrigle SA; Prizeman G; Spillane C; Byrne N; Drury A; Polus M; Mockler D; Connolly EM; Brady AM; Hanhauser YP
BMJ Open; 2024 Jun; 14(6):e076876. PubMed ID: 38871662
[TBL] [Abstract][Full Text] [Related]
6. A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
Harmsen MG; Steenbeek MP; Hoogerbrugge N; van Doorn HC; Gaarenstroom KN; Vos MC; Massuger LFAG; de Hullu JA; Hermens RPMG
Health Expect; 2018 Jun; 21(3):659-667. PubMed ID: 29281161
[TBL] [Abstract][Full Text] [Related]
7. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
[TBL] [Abstract][Full Text] [Related]
8. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.
Petrova D; Cruz M; Sánchez MJ
Breast; 2022 Feb; 61():66-76. PubMed ID: 34920368
[TBL] [Abstract][Full Text] [Related]
10. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
12. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
Isselhard A; Töpper M; Berger-Höger B; Steckelberg A; Fischer H; Vitinius F; Beifus K; Köberlein-Neu J; Wiedemann R; Rhiem K; Schmutzler R; Stock S
Trials; 2020 Jun; 21(1):501. PubMed ID: 32513307
[TBL] [Abstract][Full Text] [Related]
13. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
14. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
Meyer P; Voigtlaender T; Bartram CR; Klaes R
Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
[TBL] [Abstract][Full Text] [Related]
15. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Steenbeek MP; van Bommel MHD; Harmsen MG; Hoogerbrugge N; van Doorn HC; Keurentjes JHM; van Beurden M; Zweemer RP; Gaarenstroom KN; Penders CGJ; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; IntHout J; de Hullu JA; Hermens RPMG
Gynecol Oncol; 2021 Nov; 163(2):371-377. PubMed ID: 34456057
[TBL] [Abstract][Full Text] [Related]
19. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
20. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
